Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761860 | 0.83 | MEN1 (0.58) | TDP1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2077257 | 0.79 | SLC40A1 (0.49) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL20365557 | 0.79 | CETP (0.50) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL29678381 | 0.79 | ALDH1A1 (0.61) | TDP1SHMT2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1680541 | 0.79 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL965253 | 0.78 | P2RX7 (0.49) | TDP1SHMT2KDRALDH1A1KDM4E | |
| SCHEMBL7888919 | 0.78 | NPC1 (0.47) | SHMT2KDRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16794590 | 0.78 | KDR (0.42) | TDP1SHMT2KDRALDH1A1KDM4E | |
| SCHEMBL22129130 | 0.78 | TDP1 (0.69) | TDP1KDRKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL23931860 | 0.77 | KDM4E (0.55) | TDP1SHMT2KDRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| WO-2020148325-A1 | NEUTRAL LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-07-23 | — | — | WO | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| WO-2013064231-A1 | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) | PHENEX PHARMACEUTICALS AG (DE) | 2013-05-10 | — | — | WO | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897387-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20080261272-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT, LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20060234283-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060234349-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1664018-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | TDP1 2968/4885SHMT2 3584/4885KDR 4148/4885 |
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | TDP1 3276/4885SHMT2 3943/4885KDR 4328/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | TDP1 4199/4885SHMT2 1111/4885KDR 1684/4885 |
| US-20080166765-A1 | FUNGAL CELL WALL SYNTHESIS GENE | ERG28, GPI, DPM1 | TDP1 3229/4885SHMT2 3795/4885KDR 4434/4885 |
| US-20060234349-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | TDP1 3276/4885SHMT2 3943/4885KDR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.